Dyadic co-learning program for men with prostate cancer and their spouses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, two-group trial enrolling patient-spouse dyads from urology outpatient and inpatient services at two hospital sites in Taiwan. After baseline questionnaires, dyads are assigned 1:1 to routine care alone or routine care plus an 8-week Dyadic Co-learning Intervention that includes weekly learning modules, a mobile app, and professional support. Outcomes will be measured by questionnaires at baseline, 10 weeks, and 16 weeks to track changes in physical symptoms, emotional well-being, and resilience. The control group receives routine care only to compare effects of the co-learning program.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For Patients:

1. Diagnosed with prostate cancer by a board-certified urologist.
2. Has either decided on a treatment plan or completed treatment within the past two years.
3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

For Spouses:

1. Must be a cohabiting spouse of the prostate cancer patient and aged 20 years or older.
2. Must have a Barthel Index score of 91 or above, indicating good functional independence.

Exclusion Criteria:

Either the patient or the spouse will be excluded if:

1. Diagnosed with another type of cancer.
2. Diagnosed with cognitive impairment or a psychiatric disorder, such as dementia, depression, or anxiety.

Where it's running

• LinKou Chang Gung Memorial Hospital
  Taoyuan, Taiwan Recruiting
• Keelung Chang Gung Memorial Hospital
  Keelung, Taiwan Not yet recruiting

Study contacts

• Principal investigator: Ching-Hui Chien — National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
• Study coordinator: Ching-Hui Chien, PhD
• Email: chinghui@ntunhs.edu.tw
• Phone: +886-2-28227101

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• Predicting prostate cancer response to neoadjuvant darolutamide with a gene biomarker

  This study tests whether a gene-based PCAI ImmunoScore can predict which high-risk localized or locally advanced prostate cancer patients will have minimal residual disease after 90–120 days of darolutamide before surgery.

  Recruiting at 2 sites Phase 2 Region Stockholm · Gothenburg and 1 other locations · NCT07617272

• Personal preferences for avoiding gynecomastia (Stage 1)

  This project will ask men with prostate cancer and high-risk biochemical recurrence what trade-offs they'd make to avoid breast-related side effects like gynecomastia.

  Recruiting St Vincent's Hospital, Sydney · Sydney, New South Wales · NCT07552922

• LaserSAFE: Quick in OR imaging to check margins during prostatectomy

  A new in‑the‑operating‑room imaging method called LaserSAFE is tested to see if it can quickly detect cancer at the edge of the prostate during surgery for patients undergoing robot-assisted prostatectomy.

  Recruiting University College, London · London · NCT07541911

• Early postoperative PSA after prostate removal as a predictor of cancer outcomes

  We will test whether early PSA levels after prostate removal can help predict long-term cancer outcomes in men undergoing radical prostatectomy.

  Recruiting Lithuanian University of Health Sciences · Kaunas, Kauno · NCT07516886

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.